An observational study in Pediatric Respiratory Diseases, Asthma and RSV Infection, sponsored by Strados Labs, Inc.. Withdrawn at 1 site in United States. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-03-16.
Sponsored by Strados Labs, Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,696 studies in Asthma with a site in United States — 135 open to participants now, 189 under way, 19 of them phase 3. Asthma · United States.
Among the 1,696 studies in Asthma with a site in United States, this one is the 316th largest by enrollment of the 330 observational ones that give a count, is one of 55 that started in 2023, is one of 335 observational ones, and was the 1,507th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →135 of the 1,696 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:
University of California, Berkeley · Sites in United States
Ages 13+
Janssen Research & Development, LLC · Sites in United States, Argentina, China and 2 more countries
Ages 18–85
Pfizer · Sites in United States, Puerto Rico
Ages 12–80
GlaxoSmithKline · Sites in United States, Argentina, Canada and 1 more country
Ages 18+
Spiro Medical, Inc. · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 4 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,696 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 151 · Phase 2 338 · Phase 3 276 · Phase 4 158
First in 1990; this study’s year is marked. 55 started in 2023.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 100 across the 1,354 interventional studies, 112 across the 330 observational. Of the 1,402 that completed or were terminated, 626 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
643 of 1,696 have an industry lead sponsor. The 10 most frequent:
Strados Labs, Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Strados Labs, Inc. has 3 studies filed under Asthma — fewer than ten, so there is no comparison to draw.
84 of the studies in Asthma with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT07645248Phase 3GlaxoSmithKlineA Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a) | 2026-12-28 |
| NCT06052267Phase 3Teva Branded Pharmaceutical Products R&D LLCA Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | 2026-12-31 |
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT07671001Phase 3GlaxoSmithKlineA Study of Depemokimab in Participants of 6 to 11 Years of Age | 2027-03-01 |
Add all 84 to your calendar (.ics) → With an account.
Among the 1,696 studies in Asthma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This observational clinical trial is designed to confirm whether RESP™ Biosensor could be deployed to support clinical decision making in challenging pediatric cases, minimize clinician-to-clinician variability in lung sound interpretation, obviate the need to disrupt change of shift or chart rounds with physicians, and create a durable archive of the patient's lung sounds for longitudinal comparison within or across hospitalizations.
pediatric subjects who are admitted to the hospital with respiratory disease, including exacerbation of chronic respiratory disease and infection of RSV or COVID-19
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: RESP™ Biosensor
The RESP Biosensor will be placed on the patient for periodic recording of auscultory sound.
Also known as: RESP
Qualification and verification of lung sounds in pediatric population using RESP Biosensor
Time frame: Periodic recording over 24 hours for inpatient stay
Acceptability and utilization of RESP Biosensor in clinicians, healthcare staff and patient families
Time frame: Periodic recording over 24 hours for inpatient stay
Limitations such as age in pediatric patients
Time frame: Periodic recording over 24 hours for inpatient stay
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Mar 2023; primary completion for Dec 2023, 9 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Strados Labs, Inc.